Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Dec;36(6):567–571. doi: 10.1111/j.1365-2125.1993.tb00416.x

Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man.

D M Newnham 1, C G Ingram 1, A Mackie 1, B J Lipworth 1
PMCID: PMC1364662  PMID: 12959274

Abstract

1 The purpose of the study was to assess the bronchorelaxant effects of the beta3-adrenoceptor agonist BRL 35135 in normal human airways. 2 Eight healthy male subjects were studied, having previously demonstrated airways responsiveness to inhaled salbutamol 200 microg, with a group mean (+/- s.e. mean) fall in airways resistance (Raw), from baseline, of 37 +/- 5%. 3 Subjects attended the laboratory on 3 separate days, having fasted and taken placebo (PL) or nadolol 20 mg (N20), 2 h previously. 4 After 30 min rest, baseline measurements of Raw, serum potassium, glucose and free fatty acid were performed before subjects were given single oral doses of BRL 35135 8 mg (BRL) or placebo BRL. Measurements were repeated 60 min after the BRL or placebo BRL were given. 5 There was a significant (P < 0.05) fall in Raw (% change from baseline, as means and 95% CI) with PL/BRL: -32(-18, -46), compared with either PL/PL: -8(5, -21), or N20/BRL: -11(2, -24). There was no significant difference between PL/PL and N20/BRL. 6 A similar pattern to Raw was observed for both of the beta2-mediated metabolic responses which were also antagonised by nadolol. For the potassium response (mmol l(-1)), there was a significant (P < 0.05) difference between PL/BRL: -0.50(-0.31, -0.69), in comparison with either PL/PL: 0.08(-0.11, 0.27) or N20/BRL: 0.09(-0.10, 0.28), but values for PL/PL and N20/BRL were not significantly different. In contrast, with the free fatty acid response (nmol 1(-1)), the increase seen with N20/BRL: 85(1.0, 171.0) was significantly (P < 0.05) different from PL/PL: 3.7(-82.3, 89.8), but was not different from PL/BRL: 132.5(46.5, 218.5). 7 In conclusion, BRL 35135 produced airways, potassium and glucose responses which were antagonised by nadolol, whereas the lipolysis response was not. This suggests that there are not functional beta3-adrenoceptors in human airways.

Full text

PDF
567

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arch J. R., Ainsworth A. T., Cawthorne M. A., Piercy V., Sennitt M. V., Thody V. E., Wilson C., Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984 May 10;309(5964):163–165. doi: 10.1038/309163a0. [DOI] [PubMed] [Google Scholar]
  2. Brown R. A., Beck J. S. Statistics on microcomputers. A non-algebraic guide to their appropriate use in biomedical research and pathology practice. 3. Analysis of variance and distribution-free methods. J Clin Pathol. 1988 Dec;41(12):1256–1262. doi: 10.1136/jcp.41.12.1256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Challiss R. A., Leighton B., Wilson S., Thurlby P. L., Arch J. R. An investigation of the beta-adrenoceptor that mediates metabolic responses to the novel agonist BRL28410 in rat soleus muscle. Biochem Pharmacol. 1988 Mar 1;37(5):947–950. doi: 10.1016/0006-2952(88)90186-4. [DOI] [PubMed] [Google Scholar]
  4. DUBOIS A. B., BOTELHO S. Y., BEDELL G. N., MARSHALL R., COMROE J. H., Jr A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. J Clin Invest. 1956 Mar;35(3):322–326. doi: 10.1172/JCI103281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DUBOIS A. B., BOTELHO S. Y., COMROE J. H., Jr A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. J Clin Invest. 1956 Mar;35(3):327–335. doi: 10.1172/JCI103282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Emorine L. J., Marullo S., Briend-Sutren M. M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A. D. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989 Sep 8;245(4922):1118–1121. doi: 10.1126/science.2570461. [DOI] [PubMed] [Google Scholar]
  7. Esbenshade T. A., Han C., Theroux T. L., Granneman J. G., Minneman K. P. Coexisting beta 1- and atypical beta-adrenergic receptors cause redundant increases in cyclic AMP in human neuroblastoma cells. Mol Pharmacol. 1992 Nov;42(5):753–759. [PubMed] [Google Scholar]
  8. Harms H. H., Zaagsma J., Van der Wal B. Beta-adrenoceptor studies. III. On the beta-adrenoceptors in rat adipose tissue. Eur J Pharmacol. 1974 Jan;25(1):87–91. doi: 10.1016/0014-2999(74)90098-3. [DOI] [PubMed] [Google Scholar]
  9. Hollenga C., Haas M., Deinum J. T., Zaagsma J. Discrepancies in lipolytic activities induced by beta-adrenoceptor agonists in human and rat adipocytes. Horm Metab Res. 1990 Jan;22(1):17–21. doi: 10.1055/s-2007-1004839. [DOI] [PubMed] [Google Scholar]
  10. Lipworth B. J., McFarlane L. C., Coutie W. J., McDevitt D. G. Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade. Eur J Clin Pharmacol. 1989;37(3):297–300. doi: 10.1007/BF00679788. [DOI] [PubMed] [Google Scholar]
  11. McLaughlin D. P., MacDonald A. Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor. Br J Pharmacol. 1991 Jun;103(2):1351–1356. doi: 10.1111/j.1476-5381.1991.tb09792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Norman B. J., Leathard H. L. Evidence that an atypical beta-adrenoceptor mediates the inhibition of spontaneous rhythmical contractions of rabbit isolated jejunum induced by ritodrine and salbutamol. Br J Pharmacol. 1990 Sep;101(1):27–30. doi: 10.1111/j.1476-5381.1990.tb12083.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Walter M., Lemoine H., Kaumann A. J. Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):159–175. doi: 10.1007/BF00500912. [DOI] [PubMed] [Google Scholar]
  14. Wheeldon N. M., McDevitt D. G., Lipworth B. J. Investigation of putative cardiac beta 3-adrenoceptors in man. Q J Med. 1993 Apr;86(4):255–261. [PubMed] [Google Scholar]
  15. William-Olsson T., Fellenius E., Björntorp P., Smith U. Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand. 1979;205(3):201–206. doi: 10.1111/j.0954-6820.1979.tb06031.x. [DOI] [PubMed] [Google Scholar]
  16. Wilson C., Wilson S., Piercy V., Sennitt M. V., Arch J. R. The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists. Eur J Pharmacol. 1984 May 4;100(3-4):309–319. doi: 10.1016/0014-2999(84)90007-4. [DOI] [PubMed] [Google Scholar]
  17. de Vente J., Bast A., Van Bree L., Zaagsma J. beta-Adrenoceptor studies. 6. Further investigations on the hybrid nature of the rat adipocyte beta-adrenoceptor. Eur J Pharmacol. 1980 Apr 11;63(1):73–83. doi: 10.1016/0014-2999(80)90118-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES